Dive Into Dollar Tr...
Health Care: Drugs
Novavax Inc. (NVAX: NASDAQ)
$2.01 -0.05 | -2.43%
05/17/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 22.08M | 14.69M | 343.00K | 325.00K |
| Cost of Sales | 13.04M | 5.07M | 0.00 | 0.00 |
| Gross Operating Profit | 9.03M | 9.62M | 343.00K | 325.00K |
| Selling, General, and Administrative Expenses | 10.99M | 11.38M | 10.80M | 11.93M |
| Research & Development | 26.06M | 17.88M | 28.03M | 25.78M |
| Operating Income before D & A (EBITDA) | -28.02M | -19.65M | -38.49M | -37.38M |
| Depreciation & Amortization | 1.65M | 1.93M | 1.62M | 1.56M |
| Interest Income | 165.00K | 136.00K | 189.00K | 285.00K |
| Other Income - Net | 1.02M | 2.50M | 2.16M | -490.00K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -28.48M | -18.94M | -37.77M | -39.15M |
| Interest Expense | 32.00K | 9.00K | 9.00K | 786.00K |
| Pre-Tax Income | -28.51M | -18.95M | -37.78M | -39.94M |
| Income Taxes | 0.00 | 412.00K | -450.00K | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -28.51M | 0.00 | -35.71M | -38.37M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -28.51M | 0.00 | -35.71M | -38.37M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -28.51M | -19.36M | -35.71M | -38.37M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-28.51M | 0.00 | -35.71M | -38.37M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -28.51M | 0.00 | -35.71M | -38.37M |
| Basic EPS from Continuing Ops. | -0.22 | -0.17 | -0.34 | -0.45 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.22 | -0.17 | -0.34 | -0.45 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.22 | -0.17 | -0.34 | -0.45 |
| Basic Normalized Net Income/Share | -0.22 | n.a. | -0.34 | -0.45 |
| EPS fr Continuing Ops. | -0.22 | -0.17 | -0.34 | -0.45 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.22 | -0.17 | -0.34 | -0.45 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.22 | -0.17 | -0.34 | -0.45 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.22 | n.a. | -0.34 | -0.45 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with NVAX
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- ContributorBreakout Stocks Of The Week...
- UserCy Winther
- UserNale's Holdings
- Contributor10 Pharma Stocks Under $3
- Contributor10 Stocks Under $3 With Upside
- Contributor10 Stocks Under $4 With Upside
- Usergdean1
- Userhisatomi
- UserBruce7677
Latest NVAX Headlines from TheStreet
- Novavax To Review Recent Findings From Vaccine Programs At World Vaccine Congress And Expo In Washington, DC 04.15.13 | 05:04 pm
- Novavax Appoints Amy B. Fix Vice President Of Regulatory Affairs 04.10.13 | 08:04 am
- Novavax Reports Positive Top-Line Results From Phase II Clinical Trial Of RSV Vaccine Candidate In Women Of Childbearing Age 04.02.13 | 04:04 pm
- Novavax Reports Progress On RSV Vaccine At The XV International Symposium On Respiratory Viral Infections 03.18.13 | 08:03 am
- 5 Stocks With Big Insider Buying 03.13.13 | 12:03 pm
- Novavax To Present At The 25th Annual ROTH Conference 03.13.13 | 12:03 pm
- Novavax, CPLB And ICGEB Collaboration Honored For Malaria Vaccine Progress At Vaccine World Summit India 2013 03.08.13 | 09:03 am
- Novavax Reports Fourth Quarter And Year-End 2012 Financial Results 03.01.13 | 08:03 am
- Novavax To Report 2012 Fourth-Quarter And Year-End Financial Results On March 1, 2013 02.22.13 | 02:02 pm
- NOVAVAX To Present At The 15th Annual Bio CEO & Investor Conference 02.07.13 | 08:02 am
Press Releases for NVAX
- U.S. Life Science Companies Raise $53 Million Through Activity Of 19 At-the-Market (ATM) Offerings In First Quarter Of 2011, Data From Brinson Patrick Securities Show - PR Newswire 06.23.11 | 07:06 am
- MLV Announces Formation Of Advisory Board And Appointment Of Dr. Rahul Singhvi As Its Founding Director - PR Newswire 06.03.11 | 10:06 am
- NOVAVAX To Present At The NOBLE FINANCIAL 7th Annual Equity Conference - PR Newswire 05.13.11 | 11:05 am
- Novavax Named Biotechnology Firm Of The Year By Tech Council Of Maryland - PR Newswire 05.11.11 | 09:05 am
- Novavax To Report First Quarter 2011 Financial Results On May 9, 2011 - PR Newswire 05.03.11 | 10:05 am
- Novavax Announces Senior Management Appointments - PR Newswire 04.26.11 | 08:04 am
- Novavax Announces Change In Leadership - PR Newswire 04.19.11 | 04:04 pm
- Novavax's VLP Influenza Vaccine Named One Of Top 100 Drugs In Development Today - PR Newswire 04.05.11 | 08:04 am
- NOVAVAX Announces Release Date Of 2010 Year-End Financial Results And Investor Conference Call - PR Newswire 03.23.11 | 02:03 pm
- NOVAVAX To Present At BIT Life Science's 3rd World Congress Of Vaccine - PR Newswire 03.22.11 | 08:03 am
Partner Headlines for NVAX
- Novavax Earnings: Everything You Must Know Now - Wall St. Cheat Sheet 05.07.13 | 10:05 am
- Novavax Initiates Phase 2 Trial of RSV Vaccine; Sees Reporting Top-Line Results in Q1 2013 - Benzinga 10.08.12 | 01:10 pm
- Johnson & Johnson Gets CERTIFIED and 4 Stocks Enjoying 52-Week Highs - Wall St. Cheat Sheet 07.19.12 | 10:07 am
- NOVAVAX Launches Phase II Clinical Trial of Seasonal Influenza Vaccine - Benzinga 03.01.12 | 04:03 pm
- Oink Oink: Profit From The Return Of Swine Flu - Benzinga 01.12.12 | 01:01 pm
- Gambling With Speculative Healthcare Stocks - Seeking Alpha 09.06.11 | 09:09 am
- Novavax Gets a Federal Grant for Developing Its Novel Flu Vaccine - AOL 03.01.11 | 08:03 pm
- UPDATE 1-FDA clears Novavax trial for anti-viral vaccine - Reuters 12.16.10 | 08:12 am
- Novavax 2Q Earnings Down on High R&D Costs - Fox Business 08.06.10 | 01:08 pm
- UPDATE 1-Novavax flu vaccine trial shows mildly positive results - Reuters 04.29.10 | 09:04 am
